title: Cellular delivery of PEGylated PLGA nanoparticles.
abstract: OBJECTIVE
  The objective of this study was to investigate the efficiency of uptake of PEGylated polylactide-co-gycolide (PLGA) nanoparticles by breast cancer cells.
  
  
  METHODS
  Nanoparticles of PLGA containing various amounts of polyethylene glycol (PEG, 5%-15%) were prepared using a double emulsion solvent evaporation method. The nanoparticles were loaded with coumarin-6 (C6) as a fluorescence marker. The particles were characterized for surface morphology, particle size, zeta potential, and for cellular uptake by 4T1 murine breast cancer cells.
  
  
  RESULTS
  Irrespective of the amount of PEG, all formulations yielded smooth spherical particles. However, a comparison of the particle size of various formulations showed bimodal distribution of particles. Each formulation was later passed through a 1.2 µm filter to obtain target size particles (114-335 nm) with zeta potentials ranging from -2.8 mV to -26.2 mV. While PLGA-PEG di-block (15% PEG) formulation showed significantly higher 4T1 cellular uptake than all other formulations, there was no statistical difference in cellular uptake among PLGA, PLGA-PEG-PLGA tri-block (10% PEG), PLGA-PEG di-block (5% PEG) and PLGA-PEG di-block (10% PEG) nanoparticles.
  
  
  CONCLUSIONS
  These preliminary findings indicated that the nanoparticle formulation prepared with 15% PEGylated PLGA showed maximum cellular uptake due to it having the smallest particle size and lowest zeta potential.
authors.affiliation: Center for Nanomedicine and Drug Delivery, Xavier College of Pharmacy, New Orleans, LA, USA.
authors.forename: Sarala
authors.initials: S
authors.lastname: Pamujula
authors.forename: Sidhartha
authors.initials: S
authors.lastname: Hazari
authors.forename: Gevoni
authors.initials: G
authors.lastname: Bolden
authors.forename: Richard A
authors.initials: RA
authors.lastname: Graves
authors.forename: Dakshinamurthy Devanga
authors.initials: DD
authors.lastname: Chinta
authors.forename: Srikanta
authors.initials: S
authors.lastname: Dash
authors.forename: Vimal
authors.initials: V
authors.lastname: Kishore
authors.forename: Tarun K
authors.initials: TK
authors.lastname: Mandal
mesh_terms: D000818:Animals; D001672:Biocompatible Materials / Q000737:chemistry*; D045744:Cell Line, Tumor; D003374:Coumarins / Q000493:pharmacokinetics*; D004337:Drug Carriers; D016503:Drug Delivery Systems; D005434:Flow Cytometry; D019344:Lactic Acid / Q000737:chemistry*; D051379:Mice; D008856:Microscopy, Fluorescence; D053758:Nanoparticles / Q000737:chemistry*; D010316:Particle Size; D011100:Polyglycolic Acid / Q000737:chemistry*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D013438:Sulfhydryl Compounds / Q000493:pharmacokinetics*
chemical_list: D001672:Biocompatible Materials; D003374:Coumarins; D004337:Drug Carriers; D013438:Sulfhydryl Compounds; C508172:coumarin-6-sulfonyl chloride; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid